NasdaqCM:ORGS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Orgenesis Inc. offers biotechnology solutions focusing on cell and gene therapies (CGTs). More Details


Snowflake Analysis

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has Orgenesis's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ORGS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-9.2%

ORGS

-2.8%

US Biotechs

-5.3%

US Market


1 Year Return

45.7%

ORGS

22.7%

US Biotechs

10.4%

US Market

Return vs Industry: ORGS exceeded the US Biotechs industry which returned 25% over the past year.

Return vs Market: ORGS exceeded the US Market which returned 12% over the past year.


Shareholder returns

ORGSIndustryMarket
7 Day-9.2%-2.8%-5.3%
30 Day-9.2%-2.6%-2.1%
90 Day-17.9%-2.5%1.7%
1 Year45.7%45.7%24.9%22.7%12.9%10.4%
3 Year-0.7%-0.7%14.3%8.6%34.3%25.4%
5 Year-12.4%-12.4%5.7%-2.0%73.7%54.3%

Price Volatility Vs. Market

How volatile is Orgenesis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Orgenesis undervalued compared to its fair value and its price relative to the market?

1.13x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ORGS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ORGS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ORGS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ORGS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ORGS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ORGS is good value based on its PB Ratio (1.1x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Orgenesis forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orgenesis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Orgenesis performed over the past 5 years?

-42.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ORGS is currently unprofitable.

Growing Profit Margin: ORGS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ORGS is unprofitable, and losses have increased over the past 5 years at a rate of 42% per year.

Accelerating Growth: Unable to compare ORGS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ORGS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.8%).


Return on Equity

High ROE: ORGS has a negative Return on Equity (-53.14%), as it is currently unprofitable.


Next Steps

Financial Health

How is Orgenesis's financial position?


Financial Position Analysis

Short Term Liabilities: ORGS's short term assets ($104.3M) exceed its short term liabilities ($19.8M).

Long Term Liabilities: ORGS's short term assets ($104.3M) exceed its long term liabilities ($11.0M).


Debt to Equity History and Analysis

Debt Level: ORGS's debt to equity ratio (12.1%) is considered satisfactory.

Reducing Debt: ORGS had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ORGS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ORGS has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 53.6% each year.


Next Steps

Dividend

What is Orgenesis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ORGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ORGS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ORGS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ORGS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ORGS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.9yrs

Average board tenure


CEO

Vered Caplan (51 yo)

6.83yrs

Tenure

US$1,398,056

Compensation

Ms. Vered Caplan, M.Sc., has been the President and Chief Executive Officer of Orgenesis Inc. since August 14, 2014. Ms. Caplan is the Sole Owner of PBD Ltd. Ms. Caplan has been the Chief Executive Officer ...


CEO Compensation Analysis

Compensation vs Market: Vered's total compensation ($USD1.40M) is above average for companies of similar size in the US market ($USD593.13K).

Compensation vs Earnings: Vered's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
Vered Caplan
Chairperson of the Board6.83yrsUS$1.40mno data
Bala Manian
Member of Advisory Board1yrno datano data
Guy Yachin
Independent Director8.42yrsUS$157.00kno data
Jay Skyler
Member of Advisory Board7.42yrsUS$9.41kno data
David Sidransky
Independent Director7.25yrsUS$181.12kno data
Yaron Adler
Independent Director8.42yrsUS$157.00k0.29%
$ 286.8k
G. Fleming
Member of Advisory Board8.42yrsUS$67.20kno data
Mario Philips
Independent Director0.75yrno datano data
Stephen Minger
Member of Advisory Board0.58yrno datano data
Ashish Nanda
Independent Director3.58yrsUS$151.06kno data
Lorenzo Piemonti
Member of Advisory Board2.42yrsno datano data
Heiko Von Leyen
Member of Advisory Board0.58yrno datano data

4.9yrs

Average Tenure

53.5yo

Average Age

Experienced Board: ORGS's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 36.9%.


Top Shareholders

Company Information

Orgenesis Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Orgenesis Inc.
  • Ticker: ORGS
  • Exchange: NasdaqCM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$100.088m
  • Shares outstanding: 22.09m
  • Website: https://www.orgenesis.com

Number of Employees


Location

  • Orgenesis Inc.
  • 20271 Goldenrod Lane
  • Germantown
  • Maryland
  • 20876
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ORGSNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDOct 2009
45OBST (Boerse-Stuttgart)YesCommon SharesDEEUROct 2009

Biography

Orgenesis Inc. offers biotechnology solutions focusing on cell and gene therapies (CGTs). The company's Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare The ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/31 01:06
End of Day Share Price2020/10/30 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.